Drugs / SYH2069
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07796477 | Nov 2026 → Sep 2027 expected | type 2 diabetes mellitus | CSPC Ouyi Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07803991 | Sep 2026 → Sep 2027 expected | obesity disorder | CSPC Ouyi Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2025-12-29 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Regulatory VOLUNTARY ANNOUNCEMENT - GLP-1/GIP RECEPTOR DUAL-BIASED AGONIST POLYPEPTIDE INJECTION (SYH2069 INJECTION) OBTAINS CLINICAL TRIAL APPROVAL IN CHINA irasia.com ↗ |
| 2025-12-05 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Regulatory VOLUNTARY ANNOUNCEMENT - GLP-1/GIP RECEPTOR DUAL-BIASED AGONIST POLYPEPTIDE INJECTION (SYH2069 INJECTION) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S. irasia.com ↗ |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-09-16 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | VOLUNTARY ANNOUNCEMENT - PHASE II CLINICAL TRIAL OF SYH2069 INJECTION FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS IN ADULT PATIENTS OFFICIALLY INITIATED AT THE FIRST CENTRE IN CHINA irasia.com ↗ |
| 2026-08-28 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | VOLUNTARY ANNOUNCEMENT - PHASE II CLINICAL TRIAL OF SYH2069 INJECTION FOR WEIGHT MANAGEMENT IN ADULT PATIENTS WITH OVERWEIGHT OR OBESITY OFFICIALLY INITIATED AT THE FIRST CENTRE IN CHINA irasia.com ↗ |
| 2025-12-29 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | VOLUNTARY ANNOUNCEMENT - GLP-1/GIP RECEPTOR DUAL-BIASED AGONIST POLYPEPTIDE INJECTION (SYH2069 INJECTION) OBTAINS CLINICAL TRIAL APPROVAL IN CHINA irasia.com ↗ |
| 2025-12-05 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | VOLUNTARY ANNOUNCEMENT - GLP-1/GIP RECEPTOR DUAL-BIASED AGONIST POLYPEPTIDE INJECTION (SYH2069 INJECTION) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S. irasia.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SYH2069 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07803991 ↗ |
| Route | Subcutaneous | “administered subcutaneously (SC), Once-Weekly (QW), 28 weeks” NCT07796477 ↗ |